GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats

Diabetes

Volumn 62, Issue 9, 2013, Pages 3261-3267

  Habegger, Kirk M ^a   Kirchner, Henriette ^a   Yi, Chun Xia ^b   Heppner, Kristy M ^a   Sweeney, Dan ^a   Ottaway, Nickki ^a   Holland, Jenna ^a   Amburgy, Sarah ^a   Raver, Christine ^a   Krishna, Radhakrishna ^a   Müller, Timo D ^b   Perez Tilve, Diego ^a   Pfluger, Paul T ^b   Obici, Silvana ^a   DiMarchi, Richard D ^c   D'Alessio, David A ^a   Seeley, Randy J ^a   Tschöp, Matthias H ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GHRELIN; RIMONABANT; CANNABINOID RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PEPTIDE; VENOM;

ABDOMINAL WALL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARIATRIC SURGERY; BODY COMPOSITION; BODY WEIGHT; CONTROLLED STUDY; DIET; DRUG EFFICACY; ENERGY BALANCE; FAT MASS; FOOD INTAKE; FORESTOMACH; GASTRIC BANDING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INSULIN RESISTANCE; LAPAROTOMY; LOWER ESOPHAGUS SPHINCTER; MALE; NONHUMAN; OBESITY; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PYLORUS; RAT; SENSORY NERVE CELL; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; EATING; GASTROPLASTY; LONG EVANS RAT; METABOLISM; STOMACH BYPASS;

ANIMALS; BODY COMPOSITION; EATING; GASTRIC BYPASS; GASTROPLASTY; GLUCAGON-LIKE PEPTIDE 1; IMMUNOHISTOCHEMISTRY; MALE; OBESITY; PEPTIDES; RATS; RATS, LONG-EVANS; RECEPTORS, CANNABINOID; RECEPTORS, GLUCAGON; VENOMS;

EID: 84887345395     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0117     Document Type: Article

References (32)

1. Kopelman PG. Obesity as a medical problem. Nature 2000;404:635-643
2. Sarwer DB, von Sydow Green A, Vetter ML, Wadden TA. Behavior therapy for obesity: where are we now? Curr Opin Endocrinol Diabetes Obes 2009; 16:347-352
3. Piya MK, Tahrani AA, Barnett AH. Emerging Treatment Options for Type 2 Diabetes. Br J Clin Pharmacol. Br J Clin Pharmacol. 4 August 2010 [Epub ahead of print]
4. Steinbrook R. Surgery for severe obesity. N Engl J Med 2004;350:1075-1079
5. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122:248-256.e245
6. Franco JV, Ruiz PA, Palermo M, Gagner M. A review of studies comparing three laparoscopic procedures in bariatric surgery: sleeve gastrectomy, Roux-en-Y gastric bypass and adjustable gastric banding. Obes Surg 2011; 21:1458-1468
7. Dixon JB, Murphy DK, Segel JE, Finkelstein EA. Impact of laparo-scopic adjustable gastric banding on type 2 diabetes. Obes Rev 2012; 13:57-67
8. Kampe J, Stefanidis A, Lockie SH, et al. Neural and humoral changes associated with the adjustable gastric band: insights from a rodent model. Int J Obes (Lond) 2012;36:1403-1411
9. Shin AC, Zheng H, Townsend RL, Sigalet DL, Berthoud HR. Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology 2010;151:1588-1597
10. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006;243:108-114
11. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8: 436-447
12. Astrup A, Carraro R, Finer N, et al.; NN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012;36:843-854
13. Wickremesekera K, Miller G, Naotunne TD, Knowles G, Stubbs RS. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg 2005;15:474-481
14. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004;89:2608-2615
15. Liu Y, Zhou Y, Wang Y, Geng D, Liu J. Roux-en-Y gastric bypass-induced improvement of glucose tolerance and insulin resistance in type 2 diabetic rats are mediated by glucagon-like peptide-1. Obes Surg 2011;21:1424-1431
16. Kampe J, Brown WA, Stefanidis A, Dixon JB, Oldfield BJ. A rodent model of adjustable gastric band surgery-implications for the understanding of underlying mechanisms. Obes Surg 2009;19:625-631
17. Fried M. The current science of gastric banding: an overview of pressure-volume theory in band adjustments. Surg Obes Relat Dis 2008;4(Suppl.): S14-S21
18. Rinaldi-Carmona M, Barth F, Héaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350:240-244
19. Cota D, Sandoval DA, Olivieri M, et al. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring) 2009;17:1641-1645
20. Chambers AP, Stefater MA, Wilson-Perez HE, et al. Similar effects of roux-en-Y gastric bypass and vertical sleeve gastrectomy on glucose regulation in rats. Physiol Behav 2011;105:120-123
21. Kohli R, Kirby M, Setchell KD, et al. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol 2010;299:G652-G660
22. Kindel TL, Yoder SM, Seeley RJ, D'Alessio DA, Tso P. Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. J Gastrointest Surg 2009;13:1762-1772
23. Busetto L, Segato G, De Marchi F, et al. Postoperative management of laparoscopic gastric banding. Obes Surg 2003;13:121-127
24. Azpiroz F, Malagelada JR. Physiological variations in canine gastric tone measured by an electronic barostat. Am J Physiol 1985;248:G229-G237
25. Axelson J, Persson P, Gagnemo-Persson R, Håkanson R. Importance of the stomach in maintaining calcium homoeostasis in the rat. Gut 1991;32:1298-1302
26. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000;404:661-671
27. Smith GP. The direct and indirect controls of meal size. Neurosci Biobehav Rev 1996;20:41-46
28. Hayes MR, Leichner TM, Zhao S, et al. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab 2011;13:320-330
29. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glu-cagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997;77:257-270
30. Yi CX, van der Vliet J, Dai J, Yin G, Ru L, Buijs RM. Ventromedial arcuate nucleus communicates peripheral metabolic information to the supra-chiasmatic nucleus. Endocrinology 2006;147:283-294
31. Renner E, Puskás N, Dobolyi A, Palkovits M. Glucagon-like peptide-1 of brainstem origin activates dorsomedial hypothalamic neurons in satiated rats. Peptides 2012;35:14-22
32. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995;7:2294-2300